Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Persistent asthma | Phase 3 | US | 01 Oct 2012 | |
Persistent asthma | Phase 3 | BG | 01 Oct 2012 | |
Persistent asthma | Phase 3 | DE | 01 Oct 2012 | |
Persistent asthma | Phase 3 | HU | 01 Oct 2012 | |
Persistent asthma | Phase 3 | PL | 01 Oct 2012 | |
Persistent asthma | Phase 3 | RO | 01 Oct 2012 | |
Persistent asthma | Phase 3 | UA | 01 Oct 2012 | |
Persistent asthma | Phase 3 | GB | 01 Oct 2012 | |
Asthma | Phase 3 | US | 01 Oct 2011 | |
Asthma | Phase 3 | PH | 01 Oct 2011 |
Phase 2/3 | 374 | Placebo | kqrkpcdwom(wxftinrurg) = rvlrwpcozm lctzajvfcm (dvoevzuiub, anztbfigvg - idiymrjrqi) View more | - | 21 Apr 2020 | ||
Phase 2/3 | 197 | (Dose 1 VR506 50 mcg) | ulclyivvqi(ptuetpmbwl) = kzjpxgmgye xvjgcpzwgn (hjzoqwedxq, ljgpzfotnl - bjjttvvvnf) View more | - | 21 Apr 2020 | ||
(Dose 2 VR506 250 mcg) | ulclyivvqi(ptuetpmbwl) = uwokjjxvxf xvjgcpzwgn (hjzoqwedxq, jymwstxwrm - ouftfrtcsr) View more |